FIELD: biotechnology.
SUBSTANCE: following are presented: antibodies and their antigen-binding fragments that bind to PD-1, a transgenic rodent producing an antibody or an antigen-binding fragment, a nucleic acid encoding an antibody or an antigen-binding fragment, a cell for producing an antibody or an antigen-binding fragment. Also the following is disclosed: a pharmaceutical composition for inducing, stimulating, or enhancing an immune response, a method for inducing, stimulating, or enhancing an immune response in a patient, a method of treating cancer in a patient, a method of reducing tumor burden in a patient, and a method of treating an infection in a patient.
EFFECT: invention is aimed at producing new antibodies that immunospecifically bind to PD-1 and induce an immune response that activates the proliferation or activity of immune cells.
27 cl, 5 tbl, 14 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) | 2013 |
|
RU2689953C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
